Reduction of proteinuria with angiotensin receptor blockers

Nature Clinical Practice Cardiovascular Medicine

Volumn 5, Issue SUPPL. 1, 2008, Pages

  Galle, Jan ^a,b  

^a Klinikum Lü denscheid   (Germany)

^b Deutsche Herzstiftung ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; CANDESARTAN; CREATININE; ENALAPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; PLACEBO; RENIN; TELMISARTAN; VALSARTAN;

ADD ON THERAPY; ALBUMINURIA; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; DIABETIC NEPHROPATHY; DISEASE COURSE; DOSAGE SCHEDULE COMPARISON; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENTIATION; EVIDENCE BASED MEDICINE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY FAILURE; LOW DRUG DOSE; MEDICAL DECISION MAKING; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEINURIA; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; RENAL PROTECTION; RENOVASCULAR DISEASE; RISK REDUCTION; TREATMENT OUTCOME; VASODILATATION;

ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; BENZOATES; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DIABETIC NEPHROPATHIES; DRUG THERAPY, COMBINATION; ENALAPRIL; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; TETRAZOLES; TREATMENT OUTCOME; VALINE;

EID: 46649084424     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio0806     Document Type: Conference Paper

References (43)

1. Ruggenenti P et al. (1998). Urinary protein excretion rate is the best independent predictor of ESRF in nondiabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). Kidney Int 53: 1209-1216
2. Brewster UC and Perazella MA (2004) The renin-angiotensin-aldosterone system and the kidney: Effects on kidney disease. Am J Med 116 263-272
3. European Society of Hypertension-European Society of Cardiology Guidelines Committee (2003) 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21: 1011-1053
4. Whitworth JA (2003) 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 21: 1983-1992
5. Zidek W et al. (2003) New recommendations of the German Hypertension League for the drug treatment of hypertension. Dtsch Med Wochenschr 128: 2468-2469
6. Dzau V and Braunwald E (1991) Resolved and unresolved issues in the prevention and treatment of coronary artery disease: A workshop consensus statement. Am Heart J 121: 1244-1263
7. Hurairah H and Ferro A (2004) The role of the endothelium in the control of vascular function. Int J Clin Pract 58: 173-183
8. Hollenberg NK et al. (1998) Pathways for angiotensin II generation in intact human tissue: Evidence from comparative pharmacological interruption of the renin system. Hypertension 32: 387-392
9. Sica DA (2003) Combination angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy: Its role in clinical practice. J Clin Hypertens (Greenwich) 5: 414-420
10. Brenner BM (2003) AMGEN International Prize: The history and future of renoprotection. Kidney Int 64: 1163-1168
11. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet 355: 253-259
12. Lewis EJ et al. (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456-1462
13. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) (1997) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349: 1857-1863
14. Maschic, G et al. (1996) Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 334: 939-945
15. Kidney Disease Outcomes Quality Initiative (K/DOQI) (2004) K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 43 (Suppl 1): S1-S290
16. Brenner BM et al. (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869
17. Remuzzi G et al. (2004) Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: A post hoc analysis of the RENAAL trial results. J Am Soc Nephrol 15: 3117-3125
18. Lewis EJ et al. (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860
19. American Diabetes Association (2002) Standards of medical care for patients with diabetes mellitus. Diabetes Care 25: 213-229
20. American Diabetes Association (2006) Standards of medical care in diabetes-2006. Diabetes Care 29 (Suppl 1): S4-S42
21. Pohl MA et al. (2005) Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: Clinical implications and limitations. J Am Soc Nephrol 16: 3027-3037
22. Gall MA et al. (1997) Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: Prospective, observational study. BMJ 314 783-788
23. Ibrahim HA et al. (2004) Relations between von Willebrand factor, markers of oxidative stress and microalbuminuria in patients with type 2 diabetes mellitus. Med Sci Mond 10: CR85-CR89
24. Leoncini G et al. (2002) Microalbuminuria is an integrated marker of subdinical organ damage in primary hypertension. J Hum Hypertens 16: 399-404
25. Wachtell K et al. (2003) Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE study. Ann Intern Med 139: 901-906
26. Parving HH et al. (2001) The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870-878
27. Viberti G and Wheeldon NM (2002) Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure-independent effect. Circulation 106: 672-678
28. Ibsen H et al. (2005) Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: Losartan intervention for endpoint reduction in hypertension study. Hypertension 45: 198-202
29. Dahlöf B et al. (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 359 995-1003
30. Battershill AJ and Scott LJ (2006) Telmisartan: A review of its use in the management of hypertension. Drugs 66: 51-83
31. Makino H et al. (2005) The telmisartan renoprotective study from incipient nephropathy to overt nephropathy - rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin II receptor blocker, telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) Study. J Int Med Res 33: 677-686
32. Barnett AH et al. (2004) Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351: 1952-1961
33. Schmieder RE et al. (2005) Effects of telmisartan versus ramipril on endothelium function of the renal vasculature in type 2 diabetes. J Hypertens 23 (Suppl): S147
34. Ravid M et al. (1998) Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intem Med 128: 982-988
35. Parving HH et al. (2004) Angiotensin receptor blockers in diabetic nephropathy: Renal and cardiovascular end points. Semin Nephrol 24: 147-157
36. National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 39 (Suppi 1): S1-S266
37. Valmadrid CT et al. (2000) The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intem Med 160 1093-1100
38. Barnett AH (2005) Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study. Acta Diabetol 42 (Suppl 1): S42-S49
39. Weber M (2003) The telmisartan Programme of Research tO show Telmisartan End-organ proteCTION (PROTECTION) programme. J Hypertens 21 (Suppl): S37-S46
40. Aranda P et al. (2005) Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies. Am J Kidney Dis 46: 1074-1079
41. Wolf G and Ritz E (2005) Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: Pathophysiology and indications. Kidney Int 67: 799-812
42. MacKinnon M et al. (2006) Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: A systematic review of the efficacy and safety data. Am J Kidney Dis 48: 8-20
43. Sengul AM et al. (2006) Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension. Diabetes Res Clin Pract 71: 210-219